Columbia University

Northwestern University

University of Illinois

Universitá Degli Studi Di Genova

Maastricht University

Ottavio Arancio

Donald W Landry

Shixian Deng

Jole Fiorito

Yan Feng

Mauro Fa

Jeffrey Claude Pelletier

Owen Anthony O'Connor

Daniel Martin Watterson

Jennifer Effie Amengual

Saktimayee Mitra Roy

Yitshak Francis

Rosa Purgatorio

Andrew Wasmuth

Luigi Scotto

Shi Xian Deng

Gregory R J Thatcher

Isaac Thomas Schiefer

Alessia Romussi

Michael L Shelanski

Jos Prickaerts

Olga Bruno

Chiara Brullo

Ernesto Fedele

Roberta Ricciarelli

Michal Luzac

Bing Gong

Joie Fiorito

Greg R Thatcher

The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.

Histone acetyltransferase activators and compositions and uses thereof

The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.

Phosphodiesterase inhibitors and uses thereof

The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38&#x3b1; MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.

MAP kinase modulators and uses thereof

The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

Histone acetyltransferase activators and uses thereof

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

The invention provides for novel cysteine protease inhibitors and compositions comprising novel cysteine protease derivatives. The invention further provides for methods for treatment of neurodegenerative diseases comprising administration novel cysteine protease inhibitors or compositions comprising novel cysteine protease inhibitors. In some embodiments, the cysteine protease inhibitors are calpain inhibitors.

Cysteine protease inhibitors and uses thereof

Compounds of formula (I), wherein Z=cyclopentyl. cyclopropylmethyl, &#x2014;CH; R'&#x2550;&#x2014;CH, CHF, X=formula (II) (III) (IV) (V) Y=&#x2014;CO; &#x2014;C&#x2550;O(CH), &#x2014;CH(OH)&#x2014;CH, &#x2014;CH&#x2014;C&#x2550;O, &#x2014;CH&#x2014;CH&#x2014;C&#x2550;O; &#x2014;CH&#x2014;CH(OH)&#x2014;CH, &#x2014;CH&#x2014;CH(OCOR)&#x2014;CHNR&#x2550; &#x2014;N(CH&#x2014;CHOH), formula (VI) (VII) (VIII) (IX) (X) (XI) R=optionally substituted C-Calkyl, optionally substituted aryl; optionally substituted aralkyl, preferably C-Calkyl, more preferably CH; and enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof; these compounds have a PDE4D inhibiting activity and can be used as a medicament for treating dementia, in particular Alzheimer disease, and for improving memory. 

Compounds having a selective PDE4D inhibiting activity

The invention provides for compounds that are phosphodiesterase inhibitors. The invention further provides for a method for screening compounds that bind to and modulate a phosphosdiesterase protein. The invention also provides methods for treating conditions associated with accumulated amyloid-beta peptide deposit accumulations by administering a phosphodiesterase-binding compound to a subject.

Growing community of inventors

New York, NY, United States of America

Ottavio Arancio